MedTrace Logo

Feasibility Study of Novel Prescription Digital Therapeutic Supporting Unobserved Buprenorphine Initiation & Adherence

NCT05412966 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2023-01-09

No results posted yet for this study

Summary

The purpose of this study is to assess feasibility of an at-home digital therapy designed to support buprenorphine initiation and adherence.

Conditions

Interventions

DEVICE

PEAR-002B

PEAR-002B is a novel prescription digital therapeutic to support unobserved buprenorphine initiation and adherence in Opioid Use Disorder

DEVICE

reSET-O

reSET-O is an FDA-authorized mobile application treatment for opioid use disorder.

Sponsors & Collaborators

  • Kaiser Foundation Research Institute

    collaborator OTHER

  • Whitman-Walker Institute, Inc.

    collaborator OTHER_GOV

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Hassman Research Institute, LLC

    collaborator UNKNOWN

  • Pear Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Michael Hassman · Hassman Research Institute, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-04
Primary Completion
2022-11-23
Completion
2022-12-16
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05412966 on ClinicalTrials.gov